Modality
mAb
MOA
TROP-2 ADC
Target
BCMA
Pathway
Epigenetic
HSACC
Development Pipeline
Preclinical
Jul 2017
→ Apr 2026
PreclinicalCurrent
NCT08320497
936 pts·ACC
2017-07→2026-03·Active
NCT04427847
2,549 pts·ACC
2018-07→2026-04·Completed
3,485 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-142w agoInterim· ACC
2026-04-066d awayInterim· ACC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Active
Preclinical
Complet…
Catalysts
Interim
2026-03-14 · 2w ago
ACC
Interim
2026-04-06 · 6d away
ACC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08320497 | Preclinical | ACC | Active | 936 | LiverFat |
| NCT04427847 | Preclinical | ACC | Completed | 2549 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 |